Removed "urgency and frequency" from #10 under the When Covered section. Added #11. "Overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication". Reference added. Senior Medical Director review 5/18/2013.

Name changed from Mutation Analysis in Fine Needle Aspirates of the Thyroid to Molecular Markers in Fine Needle Aspirates of the Thyroid. Description section updated. Reference to Mutation Analysis changed to Molecular Markers throughout policy as necessary. The When Not covered statement changed from "Mutation analysis in fine-needle aspirates of the thyroid that are cytologically considered to be indeterminate, atypical or suspicious for malignancy is considered to be investigational." to "Mutation analysis in fine-needle aspirates of the thyroid is considered to be investigational. The use of a gene expression classifier in fine-needle aspirates of the thyroid that are cytologically considered to be indeterminate, atypical or suspicious for malignancy, is considered to be investigational." Policy Guidelines updated. Added "Diagnoses that are subject to medical necessity review: 241, 241.0, 241.1, 241.9 to the Billing/Coding section. No change to policy intent. Senior Medical Director review 5/18/13. References added.

Reference added. Medical Director review. Rationale updated with the following statement: "Finally, based on initial data, V3 deep sequencing (i.e. next generation sequencing) compared to ESTA or standard third variable (V3)-genotyping may identify additional patients who are unlikely to benefit from CCR5 inhibitor treatment. However, various aspects of the method are not yet standardized for this application and V3 deep sequencing for tropism determination is therefore not recommended." No change to Guideline statement.